Cosmetic vs Drug: How the FDA Classifies Products and Why It Matters for Foreign Manufacturers

One of the most consequential regulatory decisions a foreign manufacturer makes when entering the US market is determining whether their product is a cosmetic, a drug, or both under FDA classification. This classification is not based on the product's ingredients, its marketing category in the manufacturer's home country, or the manufacturer's own characterization of the product — it is determined by the product's intended use, which the FDA infers primarily from the claims made in labeling, advertising, and marketing materials. A moisturizer is a cosmetic. A moisturizer that claims to treat eczema is a drug. A moisturizer that claims to reduce the appearance of fine lines is a cosmetic. A moisturizer that claims to eliminate wrinkles by altering skin structure is a drug. The difference between these products may be nothing more than the words on the label, but the regulatory consequences are enormous.

The legal definitions under the FD&C Act

The Federal Food, Drug, and Cosmetic Act defines a cosmetic in Section 201(i) as an article intended to be rubbed, poured, sprinkled, or sprayed on, introduced into, or otherwise applied to the human body for cleansing, beautifying, promoting attractiveness, or altering the appearance. Section 201(g) defines a drug as an article intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, or intended to affect the structure or any function of the body. The critical word in both definitions is 'intended' — and the FDA determines intended use based on the totality of the product's presentation, including label claims, advertising, website descriptions, social media posts, and any other materials that suggest how the product should be used.

Importantly, the term 'cosmeceutical' has no legal meaning in the United States. The FDA does not recognize a category between cosmetics and drugs. A product is either a cosmetic, a drug, or both — there is no intermediate classification. Foreign manufacturers who market their products as 'cosmeceuticals' in other markets must understand that this term cannot be used in US labeling and that the product must be classified under one of the FDA's recognized categories.

Products that are both cosmetics and drugs

Some products meet both the cosmetic and drug definitions simultaneously. A shampoo that cleans hair is a cosmetic; an anti-dandruff shampoo that cleans hair and treats dandruff is both a cosmetic and a drug. A lip balm that moisturizes lips is a cosmetic; a lip balm with SPF that moisturizes and protects from UV radiation is both a cosmetic and a drug. Other common dual-classification products include fluoride toothpaste, antiperspirant deodorants, acne cleansers, and skin lightening creams that claim to reduce melanin production. These products must comply with both the cosmetic regulations and the applicable drug regulations — which typically means OTC drug monograph compliance, drug establishment registration, NDC labeling, and Drug Facts panel formatting.

Claims that trigger drug classification

The FDA has issued numerous Warning Letters and enforcement actions based on product claims that cross the line from cosmetic to drug. Claims that trigger drug classification include any claim to treat, cure, prevent, or mitigate a disease or medical condition (such as 'treats acne,' 'heals eczema,' 'prevents hair loss,' or 'cures fungal infection'), any claim to affect the structure or function of the body beyond merely altering appearance (such as 'stimulates collagen production,' 'increases cell turnover,' 'penetrates the dermis,' or 'strengthens the skin barrier'), and any claim that references a specific medical condition (such as 'for rosacea-prone skin' or 'dermatitis relief'). Foreign manufacturers must review every claim on their labels, websites, social media accounts, and marketing materials against these criteria before entering the US market.

Consequences of wrong classification

A product that is classified as a cosmetic but makes drug claims is an unapproved new drug — which is one of the most serious violations in the FDA's enforcement framework. Selling an unapproved new drug can result in Warning Letters, product seizure, import detention, injunctions, and criminal prosecution. The FDA routinely monitors websites, Amazon listings, and social media for drug claims made about cosmetic products, and enforcement actions against foreign brands have increased significantly since MoCRA expanded the FDA's oversight of the cosmetics market. Conversely, a product that is a drug but is registered only as a cosmetic is missing its drug establishment registration, NDC labeler code, drug listing, and Drug Facts panel — each of which is an independent violation.

How FDABridge helps with product classification

FDABridge helps foreign manufacturers determine the correct FDA classification for their products before entering the US market. Our team evaluates your product claims, formulations, and marketing materials to identify whether each product should be registered as a cosmetic under MoCRA, as an OTC drug, or as both. This classification assessment is the essential first step before filing any FDA registrations. Visit fdabridge.com/cosmetics for cosmetics services, fdabridge.com/drug for drug registration services, or fdabridge.com/contact to discuss your products.